Skip to main content

FDA Panel Backs Ketamine-like Drug for Depression

By
A person holding up a bottle of Ketamin

Despite the panel's approval, two of five key studies of esketamine failed to meet their primary goals. When taking esketamine, some patients experienced sedation, blood pressure spikes and dissociation (feeling disconnected from surroundings) within two hours of taking the drug, CNN reported.



from WebMD Health https://wb.md/2N341Ss
via IFTTT
Labels:

Comments

Post a Comment

Popular posts from this blog

The Future of Autoimmune Disorders: Psoriatic Disease

By
What's being done to help people with psoriatic disease? We get a look at the ever-changing picture from a rheumatologist. from WebMD Health https://ift.tt/5P6ZHyd via IFTTT
Post a Comment
Read more

Study: Black Men Twice as Likely to Develop Prostate Cancer as Whites

By
A review of men seen at VA hospitals found that Black veterans had nearly twice the incidence of localized and advanced prostate cancer as white men. from WebMD Health https://ift.tt/3Knscs2 via IFTTT
Post a Comment
Read more

Long COVID Experts: ‘So Incredibly Clear What’s at Stake’

By
It’s estimated that more than a third of people who have had COVID-19 experience neurological complications such as brain fog that persist or develop 3 months after infection. And two thirds of so-called long haulers still have neurological symptoms after 6 months. from WebMD Health https://ift.tt/mx1j6QD via IFTTT
Post a Comment
Read more